<DOC>
	<DOC>NCT00086242</DOC>
	<brief_summary>RATIONALE: Telephone counseling after treatment may reduce stress and improve the well-being and quality of life of patients who have cervical cancer. Changes in quality of life may be related to changes in immune function and neuroendocrine function. PURPOSE: This randomized phase I trial is studying how well telephone counseling works compared to standard care in reducing stress in patients who have completed treatment for stage I, stage II, or stage III cervical cancer.</brief_summary>
	<brief_title>Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stage I, Stage II, or Stage III Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES: - Compare quality of life (QOL) at baseline and changes in QOL, immune response, and neuroendocrine parameters over time in patients who have completed treatment for stage I-III cervical cancer receiving psychosocial telephone counseling vs usual care. - Correlate psychosocial measures with immunologic stance. OUTLINE: This is a randomized, controlled, parallel-group study. Patients are randomized to 1 of 2 intervention arms. - Arm I: Patients undergo psychosocial telephone counseling comprising 5 weekly sessions and a 1-month follow-up session to learn strategies for reducing stress. - Arm II: Patients undergo usual care for approximately 4 months. All patients complete questionnaires and Quality of life assessment at baseline and at 4 months. They also undergo saliva and blood sample collections at baseline and at 4 months for neuroimmune studies. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS: Diagnosis of cervical cancer between the past 315 months Stage IIII disease Completed therapy for cervical cancer â‰¥ 1 month ago Not receiving ongoing treatment PATIENT CHARACTERISTICS: Resident of Orange, San Diego, or Imperial County in California English or Spanish speaking No serious acute or chronic illness Has access to a telephone PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 4 weeks since prior immunotherapy More than 30 days since prior investigational drugs No prior biological response modifier No concurrent corticosteroids No concurrent immunosuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>psychosocial effects of cancer and its treatment</keyword>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
</DOC>